|
US5618920A
(en)
|
1985-11-01 |
1997-04-08 |
Xoma Corporation |
Modular assembly of antibody genes, antibodies prepared thereby and use
|
|
US4801575A
(en)
|
1986-07-30 |
1989-01-31 |
The Regents Of The University Of California |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4902505A
(en)
|
1986-07-30 |
1990-02-20 |
Alkermes |
Chimeric peptides for neuropeptide delivery through the blood-brain barrier
|
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
|
US5530101A
(en)
|
1988-12-28 |
1996-06-25 |
Protein Design Labs, Inc. |
Humanized immunoglobulins
|
|
US5180820A
(en)
|
1989-08-30 |
1993-01-19 |
Barde Yves Alain |
Brain-derived neurotrophic factor
|
|
US5229500A
(en)
|
1989-08-30 |
1993-07-20 |
Regeneron Pharmaceuticals, Inc. |
Brain derived neurotrophic factor
|
|
US6541610B1
(en)
|
1989-09-05 |
2003-04-01 |
Immunex Corporation |
Fusion proteins comprising tumor necrosis factor receptor
|
|
NZ235148A
(en)
|
1989-09-05 |
1991-12-23 |
Immunex Corp |
Tumour necrosis factor receptor protein and dna sequences
|
|
US5977307A
(en)
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
|
US5182107A
(en)
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
US5154924A
(en)
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
US5527527A
(en)
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
|
US5672683A
(en)
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
|
DE10399023I2
(de)
|
1989-09-12 |
2006-11-23 |
Ahp Mfg B V |
TFN-bindende Proteine
|
|
US5527288A
(en)
|
1990-12-13 |
1996-06-18 |
Elan Medical Technologies Limited |
Intradermal drug delivery device and method for intradermal delivery of drugs
|
|
TW279133B
(enExample)
|
1990-12-13 |
1996-06-21 |
Elan Med Tech |
|
|
US6060069A
(en)
|
1991-05-20 |
2000-05-09 |
Dura Pharmaceuticals, Inc. |
Pulmonary delivery of pharmaceuticals
|
|
US6287792B1
(en)
|
1991-06-17 |
2001-09-11 |
The Regents Of The University Of California |
Drug delivery of antisense oligonucleotides and peptides to tissues in vivo and to cells using avidin-biotin technology
|
|
ATE188708T1
(de)
|
1991-08-21 |
2000-01-15 |
Novartis Ag |
Antikörperderivate
|
|
MX9205293A
(es)
|
1991-09-20 |
1993-05-01 |
Syntex Sinergen Neuroscience J |
Factores neurotrofico derivado del glial
|
|
JPH06228199A
(ja)
|
1992-11-27 |
1994-08-16 |
Takeda Chem Ind Ltd |
血液脳関門通過可能なペプチド結合体
|
|
CA2115900A1
(en)
|
1993-02-22 |
1994-08-23 |
Gerald W. Becker |
Pharmaceutical screens and antibodies
|
|
US6195608B1
(en)
|
1993-05-28 |
2001-02-27 |
Lucent Technologies Inc. |
Acoustic highway monitor
|
|
US5997501A
(en)
|
1993-11-18 |
1999-12-07 |
Elan Corporation, Plc |
Intradermal drug delivery device
|
|
EP0706799B1
(en)
|
1994-09-16 |
2001-11-14 |
MERCK PATENT GmbH |
Immunoconjugates II
|
|
US5656284A
(en)
|
1995-04-24 |
1997-08-12 |
Balkin; Michael S. |
Oral transmucosal delivery tablet and method of making it
|
|
AU6163196A
(en)
|
1995-06-07 |
1996-12-30 |
Smithkline Beecham Corporation |
Method for obtaining receptor agonist antibodies
|
|
DE69630798T2
(de)
|
1995-09-19 |
2004-09-23 |
Fujisawa Pharmaceutical Co., Ltd. |
Aerosolzusammensetzungen
|
|
US6015662A
(en)
|
1996-01-23 |
2000-01-18 |
Abbott Laboratories |
Reagents for use as calibrators and controls
|
|
US5837231A
(en)
|
1996-06-27 |
1998-11-17 |
Regents Of The University Of Minnesota |
GM-CSF administration for the treatment and prevention of recurrence of brain tumors
|
|
US6030803A
(en)
|
1996-07-16 |
2000-02-29 |
De Staat Der Nederlanden, Vertegenwoordigd Door De Minister Van Welzijn, Volksgeszonheid En Cultuur |
Dibenzodihydropyridinecarboxylic esters and their use in chemiluminescent assay methods
|
|
US8173127B2
(en)
|
1997-04-09 |
2012-05-08 |
Intellect Neurosciences, Inc. |
Specific antibodies to amyloid beta peptide, pharmaceutical compositions and methods of use thereof
|
|
AU8269898A
(en)
|
1997-06-27 |
1999-01-19 |
Regents Of The University Of California, The |
Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor
|
|
WO1999000951A1
(en)
|
1997-06-30 |
1999-01-07 |
Motorola Inc. |
Circuit and packet switched network interconnection
|
|
US6165476A
(en)
|
1997-07-10 |
2000-12-26 |
Beth Israel Deaconess Medical Center |
Fusion proteins with an immunoglobulin hinge region linker
|
|
US6482923B1
(en)
|
1997-09-17 |
2002-11-19 |
Human Genome Sciences, Inc. |
Interleukin 17-like receptor protein
|
|
US6016800A
(en)
|
1997-10-24 |
2000-01-25 |
Century; Theodore J. |
Intrapulmonary aerosolizer
|
|
US6165783A
(en)
|
1997-10-24 |
2000-12-26 |
Neuro Spheres Holdings Ltd. |
Erythropoietin-mediated neurogenesis
|
|
US6905686B1
(en)
|
1997-12-02 |
2005-06-14 |
Neuralab Limited |
Active immunization for treatment of alzheimer's disease
|
|
DE69839969D1
(de)
|
1997-12-11 |
2008-10-16 |
Alza Corp |
Vorrichtung zur verbesserung des transdermalen flusses von medikamenten
|
|
JP4334141B2
(ja)
|
1998-04-20 |
2009-09-30 |
グリカート バイオテクノロジー アクチェンゲゼルシャフト |
抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
|
|
JP4113670B2
(ja)
|
1998-06-22 |
2008-07-09 |
イムノメディクス, インコーポレイテッド |
プレターゲッティング診断およびプレターゲッティング治療のための二重特異性抗体の使用
|
|
US6348210B1
(en)
|
1998-11-13 |
2002-02-19 |
Alza Corporation |
Methods for transdermal drug administration
|
|
US6375975B1
(en)
|
1998-12-21 |
2002-04-23 |
Generex Pharmaceuticals Incorporated |
Pharmaceutical compositions for buccal and pulmonary application
|
|
EP2016953A3
(en)
|
1998-12-22 |
2009-04-15 |
Genentech, Inc. |
Vascular endothelial cell growth factor antagonists and uses thereof
|
|
US6284262B1
(en)
|
1999-01-26 |
2001-09-04 |
Virgil A. Place |
Compact dosage unit for buccal administration of a pharmacologically active agent
|
|
US7214658B2
(en)
|
2004-07-06 |
2007-05-08 |
Tact Ip, Llc |
Method of delivering a TNF antagonist to the brain of a human by perispinal administration without direct intrathecal injection
|
|
WO2000051621A1
(en)
|
1999-03-05 |
2000-09-08 |
Epigenesis Pharmaceuticals, Inc. |
Method for validating/invalidating target(s) and pathways
|
|
US7309687B1
(en)
|
1999-04-13 |
2007-12-18 |
The Kenneth S. Warren Institute, Inc. |
Methods for treatment and prevention of neuromuscular and muscular conditions by peripherally administered erythropoietin
|
|
DK1409654T3
(da)
|
1999-06-16 |
2008-12-08 |
Boston Biomedical Res Inst |
Immunologisk styring af beta-amyloid-niveauer in vivo
|
|
CZ299516B6
(cs)
|
1999-07-02 |
2008-08-20 |
F. Hoffmann-La Roche Ag |
Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
|
|
AU6607100A
(en)
|
1999-07-23 |
2001-02-13 |
Regents Of The University Of California, The |
Anti-growth factor receptor avidin fusion proteins as universal vectors for drugdelivery
|
|
JP3589912B2
(ja)
|
1999-09-03 |
2004-11-17 |
泰久 福井 |
ホスファチジルイノシトール−3,4−二リン酸を認識するモノクローナル抗体
|
|
US20020052311A1
(en)
|
1999-09-03 |
2002-05-02 |
Beka Solomon |
Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
|
|
US6195605B1
(en)
|
1999-09-29 |
2001-02-27 |
Bmi Technologies Inc. |
Impact monitor
|
|
US6585971B1
(en)
|
1999-11-12 |
2003-07-01 |
Harbor-Ucla Research And Education Institute |
Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating disease caused by deficiencies thereof
|
|
AU782067B2
(en)
|
1999-12-20 |
2005-06-30 |
Immunex Corporation |
TWEAK receptor
|
|
US6248262B1
(en)
|
2000-02-03 |
2001-06-19 |
General Electric Company |
Carbon-reinforced thermoplastic resin composition and articles made from same
|
|
CA2401645A1
(en)
|
2000-02-29 |
2001-09-07 |
Lexicon Genetics Incorporated |
Novel human transporter proteins and polynucleotides encoding the same
|
|
US6372250B1
(en)
|
2000-04-25 |
2002-04-16 |
The Regents Of The University Of California |
Non-invasive gene targeting to the brain
|
|
US6696274B2
(en)
|
2000-05-03 |
2004-02-24 |
Supratek Pharma, Inc. |
Ligand for enhancing oral and CNS delivery of biological agents
|
|
US7078376B1
(en)
|
2000-08-11 |
2006-07-18 |
Baxter Healthcare S.A. |
Therapeutic methods for treating subjects with a recombinant erythropoietin having high activity and reduced side effects
|
|
WO2002055736A2
(en)
|
2000-12-04 |
2002-07-18 |
Univ California |
Antisense imaging of gene expression of the brain in vivo
|
|
KR100896971B1
(ko)
|
2001-02-02 |
2009-05-14 |
오르토-맥네일 파마슈티칼, 인코퍼레이티드 |
프락토피라노오스 설파메이트 및 에리트로포이에틴을포함하는 신경계 기능장애 치료법
|
|
RU2003125637A
(ru)
|
2001-02-06 |
2005-03-10 |
Мерк Патент ГмбХ (DE) |
Модифицированный нейтрофический фактор выделенный из мозга человека (bdnf) с уменьшенной иммуногенностью
|
|
US8163289B2
(en)
|
2001-03-09 |
2012-04-24 |
Iterative Therapeutics, Inc. |
Methods and compositions involving polymeric immunoglobulin fusion proteins
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
ATE384736T1
(de)
|
2001-04-30 |
2008-02-15 |
Zystor Therapeutics Inc |
Subzelluläres targeting von therapeutischen proteinen
|
|
US20040005309A1
(en)
|
2002-05-29 |
2004-01-08 |
Symbiontics, Inc. |
Targeted therapeutic proteins
|
|
US7629309B2
(en)
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
JP4202250B2
(ja)
|
2001-07-25 |
2008-12-24 |
バイオマリン ファーマシューティカル インコーポレイテッド |
血液脳関門輸送を調節するための組成物および方法
|
|
ES2391905T3
(es)
|
2001-08-17 |
2012-11-30 |
Washington University |
Método de ensayo para la enfermedad de alzheimer
|
|
US7125843B2
(en)
|
2001-10-19 |
2006-10-24 |
Neose Technologies, Inc. |
Glycoconjugates including more than one peptide
|
|
WO2003032913A2
(en)
|
2001-10-16 |
2003-04-24 |
Symbiontics Inc. |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
US7053202B2
(en)
|
2001-10-19 |
2006-05-30 |
Millennium Pharmaceuticals, Inc. |
Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
|
|
EP1514106A4
(en)
|
2002-05-29 |
2007-05-09 |
Zystor Therapeutics Inc |
TARGETED THERAPEUTIC PROTEINS
|
|
DK1517921T3
(da)
|
2002-06-28 |
2006-10-09 |
Domantis Ltd |
Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
|
|
US20040102369A1
(en)
|
2002-11-27 |
2004-05-27 |
The Regents Of The University Of California |
Transport of basic fibroblast growth factor across the blood brain barrier
|
|
US20050142141A1
(en)
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
US7388079B2
(en)
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
ZA200506159B
(en)
*
|
2003-02-10 |
2006-10-25 |
Elan Pharm Inc |
Immunoglobulin formulation and method of preparation thereof
|
|
US8227212B2
(en)
*
|
2003-02-11 |
2012-07-24 |
Shire Human Genetic Therapies, Inc. |
Cell that expresses a sulfatase and a formylglycine generating enzyme
|
|
DK1610820T4
(da)
|
2003-04-04 |
2013-11-04 |
Genentech Inc |
Høj-koncentration antistof- og proteinformuleringer
|
|
WO2004108071A2
(en)
|
2003-06-05 |
2004-12-16 |
Salk Institute For Biological Studies |
Targeting polypeptides to the central nervous system
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
WO2005000898A2
(en)
|
2003-06-27 |
2005-01-06 |
Biogen Idec Ma Inc. |
Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions
|
|
US7112299B2
(en)
|
2003-07-09 |
2006-09-26 |
Michael Merrick |
Systems and methods for fabricating composite fiberglass laminate articles
|
|
US7294704B2
(en)
|
2003-08-15 |
2007-11-13 |
Diadexus, Inc. |
Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk
|
|
EP1548031A1
(en)
|
2003-12-22 |
2005-06-29 |
Dubai Genetics FZ-LLC |
Nature-identical erythropoietin
|
|
NZ548871A
(en)
|
2004-01-30 |
2009-06-26 |
Shire Pharmaceuticals Ireland |
Use of arylsulfatase A for treating metachromatic leukodystrophy
|
|
ES2344302T3
(es)
|
2004-02-10 |
2010-08-24 |
Zystor Therapeutics , Inc. |
Alfa glucosidasa acida y fragmentos de la misma.
|
|
EP1713502A1
(de)
*
|
2004-02-12 |
2006-10-25 |
MERCK PATENT GmbH |
Hochkonzentrierte, flüssige formulierungen von anti-egfr-antikörpern
|
|
US7939490B2
(en)
|
2004-12-13 |
2011-05-10 |
University Of Maryland, Baltimore |
TWEAK as a therapeutic target for treating central nervous system diseases associated with cerebral edema and cell death
|
|
WO2006074399A2
(en)
|
2005-01-05 |
2006-07-13 |
Biogen Idec Ma Inc. |
Multispecific binding molecules comprising connecting peptides
|
|
EP1841455A1
(en)
|
2005-01-24 |
2007-10-10 |
Amgen Inc. |
Humanized anti-amyloid antibody
|
|
WO2006108052A2
(en)
|
2005-04-06 |
2006-10-12 |
Genzyme Corporation |
Peg and polysialic lysosomal enzyme conjugates via acid labile linkers for therapeutic targeting
|
|
US7932032B2
(en)
|
2005-05-02 |
2011-04-26 |
Toray Industries, Inc. |
Method for diagnosing esophageal cancer
|
|
WO2007019232A2
(en)
|
2005-08-03 |
2007-02-15 |
Immunogen, Inc. |
Immunoconjugate formulations
|
|
WO2007022416A2
(en)
|
2005-08-18 |
2007-02-22 |
Ramot At Tel Aviv University Ltd. |
Single chain antibodies against beta-amyloid peptide
|
|
WO2007044468A2
(en)
|
2005-10-05 |
2007-04-19 |
The Cbr Institute For Biomedical Research, Inc. |
Method to treat flavivirus infection with sirna
|
|
US8124095B2
(en)
|
2005-10-07 |
2012-02-28 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of erythropoietin to the CNS
|
|
US8741260B2
(en)
|
2005-10-07 |
2014-06-03 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of GDNF to the CNS
|
|
US8142781B2
(en)
|
2005-10-07 |
2012-03-27 |
Armagen Technologies, Inc. |
Fusion proteins for blood-brain barrier delivery
|
|
JP4860702B2
(ja)
|
2005-10-21 |
2012-01-25 |
エフ.ホフマン−ラ ロシュ アーゲー |
ポリペプチドのリコンビナント発現のための方法
|
|
IL193282A
(en)
|
2006-02-06 |
2013-04-30 |
Yeda Res & Dev |
Chimeric protein of therapeutic enzyme and granulocyte-stimulating factor for treatment of lysosomal storage diseases
|
|
CA2641070C
(en)
|
2006-02-06 |
2017-01-03 |
Ramot At Tel-Aviv University Ltd. |
Enzyme replacement therapy for treating lysosomal storage diseases
|
|
US7981417B2
(en)
|
2006-06-07 |
2011-07-19 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting anti-bodies
|
|
EP2029621A2
(en)
|
2006-06-07 |
2009-03-04 |
Wisconsin Alumni Research Foundation |
Blood-brain barrier targeting antibodies
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
WO2008022349A2
(en)
|
2006-08-18 |
2008-02-21 |
Armagen Technologies, Inc. |
Agents for blood-brain barrier delivery
|
|
US9388425B2
(en)
|
2006-10-20 |
2016-07-12 |
Trustees Of Boston University |
Tunable genetic switch for regulating gene expression
|
|
JP2010510794A
(ja)
|
2006-11-28 |
2010-04-08 |
ハナル ファーマシューティカル カンパニー リミテッド |
修飾型エリスロポエチンポリペプチド及びこの治療用用途
|
|
EP2167115A2
(en)
|
2007-06-15 |
2010-03-31 |
University Of Zurich |
Treatment for alzheimer's disease
|
|
CA2694762A1
(en)
|
2007-07-27 |
2009-02-05 |
Armagen Technologies, Inc. |
Methods and compositions for increasing alpha-l-iduronidase activity in the cns
|
|
WO2009070597A2
(en)
|
2007-11-26 |
2009-06-04 |
Armagen Technologies, Inc. |
Fusion proteins for delivery of gdnf to the cns
|
|
US20110223147A1
(en)
|
2008-05-07 |
2011-09-15 |
Zystor Therapeutics, Inc. |
Lysosomal targeting peptides and uses thereof
|
|
US8632774B2
(en)
|
2008-07-02 |
2014-01-21 |
Emergent Product Development Seattle, Llc |
Antagonists of IL-6
|
|
US20100077498A1
(en)
|
2008-09-11 |
2010-03-25 |
Pardridge William M |
Compositions and methods for blood-brain barrier delivery in the mouse
|
|
US20100098693A1
(en)
|
2008-10-07 |
2010-04-22 |
Pardridge William M |
Compositions and methods for blood-brain barrier delivery of organophosphatases
|
|
AU2009327267A1
(en)
|
2008-12-17 |
2011-07-14 |
Angiochem, Inc. |
Membrane type-1 matrix metalloprotein inhibitors and uses thereof
|
|
EP2408474B1
(en)
|
2009-03-18 |
2019-06-26 |
Armagen, Inc. |
Compositions and methods for blood-brain barrier delivery of igg-decoy receptor fusion proteins
|
|
WO2010141932A1
(en)
|
2009-06-05 |
2010-12-09 |
Link Medicine Corporation |
Aminopyrrolidinone derivatives and uses thereof
|
|
ES2618894T3
(es)
|
2009-06-24 |
2017-06-22 |
Curna, Inc. |
Tratamiento de enfermedades relacionadas con el receptor del factor de necrosis tumoral 2 (tnfr2) por inhibición del transcrito natural antisentido para tnfr2
|
|
HUE044865T2
(hu)
|
2009-10-09 |
2019-11-28 |
Armagen Inc |
Eljárások és készítmények a központi idegrendszerben iduronát-2-szulfatáz-aktivitás növelésére
|
|
HRP20191924T1
(hr)
|
2010-06-25 |
2020-01-10 |
Shire Human Genetic Therapies, Inc. |
Postupci i sastavi za isporuku iduronat-2-sulfataze u cns
|
|
US20110318327A1
(en)
|
2010-06-25 |
2011-12-29 |
Shire Human Genetic Therapies, Inc. |
Treatment of sanfilippo syndrome type b
|
|
PT3626258T
(pt)
|
2010-06-25 |
2021-10-19 |
Shire Human Genetic Therapies |
Métodos e composições para fornecimento ao snc de iduronato-2-sulfatase
|
|
MX2013000320A
(es)
|
2010-06-25 |
2013-06-05 |
Shire Human Genetic Therapies |
Composiciones y metodos para suministro al sistema nervioso central de heparan n-sulfatasa.
|
|
EA034333B1
(ru)
|
2010-11-30 |
2020-01-29 |
Дженентек, Инк. |
Варианты антитела для переноса соединения через гематоэнцефалический барьер
|
|
WO2012085622A1
(en)
|
2010-12-22 |
2012-06-28 |
Fondazione Telethon |
Therapeutic strategies to treat cns pathology in mucopolysaccharidoses
|
|
US8580922B2
(en)
|
2011-03-04 |
2013-11-12 |
Shire Human Genetic Therapies, Inc. |
Peptide linkers for polypeptide compositions and methods for using same
|
|
US20130039888A1
(en)
|
2011-06-08 |
2013-02-14 |
Nationwide Children's Hospital Inc. |
Products and methods for delivery of polynucleotides by adeno-associated virus for lysosomal storage disorders
|
|
US9845327B2
(en)
|
2011-06-22 |
2017-12-19 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
WO2013052915A2
(en)
|
2011-10-05 |
2013-04-11 |
Genelux Corporation |
Method for detecting replication or colonization of a biological therapeutic
|
|
JP6329483B2
(ja)
|
2011-10-12 |
2018-05-23 |
シナジェバ・バイオファーマ・コーポレイションSynageva Biopharma Corp. |
組換えヒトnagluタンパク質およびその利用
|
|
ES2983576T3
(es)
|
2011-12-02 |
2024-10-23 |
Armagen Inc |
Métodos y composiciones para aumentar la actividad arilsulfatasa en el SNC
|
|
WO2013181454A1
(en)
|
2012-05-30 |
2013-12-05 |
Biostrategies LC |
Plant lectins as carriers of associated drug substances into animal and human cells
|
|
KR101380740B1
(ko)
|
2012-06-29 |
2014-04-11 |
쉐어 휴먼 제네텍 세러피스, 인코포레이티드 |
이듀로네이트-2-설파타제의 정제
|
|
EP2880057A4
(en)
|
2012-08-02 |
2016-03-23 |
Jn Biosciences Llc |
MULTIMERIZED FUSION ANTIBODIES OR PROTEINS THROUGH THE MUTATION OF A CYSTEINE AND A PIECE OF TAIL
|
|
CA2888628A1
(en)
|
2012-10-19 |
2014-04-24 |
Tokushima University |
Novel high functional enzyme having modified substrate specificity of human beta-hexosaminidase b and exhibiting protease resistance
|
|
JP6083219B2
(ja)
|
2012-12-06 |
2017-02-22 |
富士通セミコンダクター株式会社 |
プラズマフラッドガン及びイオン注入装置
|
|
US20140354655A1
(en)
|
2013-06-04 |
2014-12-04 |
Qualcomm Mems Technologies, Inc. |
Reducing floating node leakage current with a feedback transistor
|
|
US10906981B2
(en)
|
2013-07-19 |
2021-02-02 |
The Regents Of The University Of California |
Compositions and methods related to structures that cross the blood brain barrier
|
|
EP3730516A1
(en)
|
2013-07-22 |
2020-10-28 |
Armagen, Inc. |
Methods and compositions for increasing enzyme activity in the cns
|
|
PL3119892T3
(pl)
|
2014-03-17 |
2021-11-29 |
The Hospital For Sick Children |
Warianty białka beta-heksozaminidazy oraz związane z nimi sposoby do leczenia gangliozydoz gm2
|
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
|
US11326182B2
(en)
|
2016-04-29 |
2022-05-10 |
Voyager Therapeutics, Inc. |
Compositions for the treatment of disease
|
|
JP6956741B2
(ja)
|
2016-12-26 |
2021-11-02 |
Jcrファーマ株式会社 |
血液脳関門を通過する新規な抗ヒトトランスフェリン受容体抗体
|
|
KR102471458B1
(ko)
|
2016-12-28 |
2022-11-25 |
제이씨알 파마 가부시키가이샤 |
동결건조 제제
|
|
EP3833689A4
(en)
|
2018-08-07 |
2022-05-25 |
Armagen, Inc. |
METHODS AND COMPOSITIONS FOR INCREASING THE ACTIVITY IN THE CENTRAL NERVOUS SYSTEM OF HEXOSAMINIDASE A, ACID SPHINGOMYELINASE AND PALMITOYL-PROTEIN THIOESTERASE 1
|
|
US20220002688A1
(en)
|
2018-12-20 |
2022-01-06 |
Armagen, Inc. |
Purification of iduronate-2-sulfatase immunoglobulin fusion protein
|
|
EP3908611A4
(en)
|
2019-01-08 |
2022-10-12 |
Armagen, Inc. |
Methods and compositions for increasing galactosidase beta-1 activity in the cns
|